Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   41 News 


12345678910111213...2627»
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis. (Pubmed Central) -  Feb 1, 2025   
    P3b
    These findings support the use of the once-daily B/F/TAF single-tablet regimen for people with HIV-1 and ESKD on HD. This regimen offers a convenient treatment option for this population as it reduces the need for dose adjustment, eases pill burden and avoids potential drug-drug interactions associated with alternatives that may impact individuals on multiple medications or awaiting transplantation.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition. (Pubmed Central) -  Jan 29, 2025   
    Our results suggest switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline in NPZ-12 and in specific domains was observed.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Observational data, Retrospective data, Journal:  Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-na (Pubmed Central) -  Jan 12, 2025   
    In prospective TN participants, improvements in bothersome symptom count and quality-of-life measures were observed. B/F/TAF demonstrated high levels of virologic effectiveness and tolerability in people with HIV treated as part of routine clinical care in Japan.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  HIV-1 viral decay in blood and semen in antiretroviral-na (Pubmed Central) -  Jan 6, 2025   
    B/F/TAF demonstrated high levels of virologic effectiveness and tolerability in people with HIV treated as part of routine clinical care in Japan. These findings indicated comparable effectiveness of DTG/3TC vs. BIC/FTC/TAF in achieving viral suppression in BP and SP, and similar changes in inflammatory biomarkers in BP.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
    Journal:  Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide. (Pubmed Central) -  Dec 16, 2024   
    N=100 --> 0 | Unknown status --> Withdrawn Standardized changes in weight, BMI, and body composition were minor and similar between participant switching to CAB+RPV LA Q2M or continuing BIC/FTC/TAF, with no clinically relevant changes in metabolic syndrome or insulin resistance.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  HIV/AIDS antiretroviral therapy initiated on the same day in treatment-na (Pubmed Central) -  Dec 3, 2024   
    No abstract available ART initiation on the day of diagnosis is effective, safe, and feasible, with satisfactory rates of virologic suppression, 48-week initial ART regimen retention rates, and treatment retention rates in treatment-na
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. (Pubmed Central) -  Nov 27, 2024   
    Here, we report long-term virological and immunological outcome in 12 virally suppressed people on short-cycle therapy with bictegravir/emtricitabine/tenofovir alafenamide administered five days a week (Monday to Friday). All patients, after a long term follow-up, were virally suppressed In the wait for new long-acting antiretroviral drugs and new antiretroviral formulations, short-cycle therapy has proven to be a safe and effective alternative to the standard daily antiretroviral regimen for individuals living with HIV who are virologically suppressed.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  High prevalence of osteoporosis among virally suppressed older people (?60?years) living with HIV. (Pubmed Central) -  Nov 21, 2024   
    The prevalence of osteoporosis is high among older people living with HIV in Kenya, where DXA is not readily available and risk calculation without BMD had low correlation with measured BMD values. Additional data are required on the impact of investment in fracture risk assessment and treatment, including population-specific risk calculators.
  • ||||||||||  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Clinical efficacy and safety of new compound single tablet antiviral drugs in the treatment of HIV/AIDS. (Pubmed Central) -  Nov 18, 2024   
    Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025 Genvoya, Biktarvy and Dovato are recommended for the treatment of HIV/AIDS and have a good safety profile.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed:  Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) (clinicaltrials.gov) -  Nov 13, 2024   
    P4,  N=33, Active, not recruiting, 
    In our real-life cohort, the effect of switching TDF-/TAF-sparing regimens to triple therapy with B/F/TAF improved total cholesterol, triglycerides, and serum markers of HS at 6?months and was neutral for the remaining metabolic parameters at 12?months. Recruiting --> Active, not recruiting
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    A case of visceral leishmaniasis presenting as seropositive erosive rheumatoid arthritis in an immunocompromised patient () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_77;    
    He was diagnosed with HIV a decade ago which was well controlled with bictegravir, emtricitabine and tenofovir alafenamide...Imaging showed lymphadenopathy and splenomegaly (17.5cm).A diagnosis of rheumatoid arthritis with possible connective tissue disease overlap was made and he was initiated on hydroxychloroquine.Because of systemic symptoms and atypical skin nodules, further investigation was undertaken including lymph node, bone marrow and skin biopsies, all of which confirmed a diagnosis of leishmaniasis...Multidisciplinary approach is key in managing such difficult cases. Our case was managed jointly by the rheumatology, dermatology and infectious disease teams, and the national leishmaniasis multidisciplinary team from University College London Hospitals.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5210;    
    Venetoclax has shown activity in other T-cell malignancies, alone or in combination with hypomethylating agents (HMA), AZT (Zidovudine) with Interferon-alpha has been the backbone of acute ATLL treatment for the past three decades...Results : Preclinical : We observed that both the J-ATLL and NA-ATLL cells are sensitive to BCL-2 inhibitors (Venetoclax & Sonrotoclax) with IC50s in the 1-10uM range...To determine synergy between drugs we tested the combination of Decitabine (hypomethylating agent)-Venetoclax as well as between Biktarvy-Venetoclax...TP53 mutated patients had poorer responses. Given the encouraging preclinical and clinical activity of this agent, a prospective clinical trial is being developed using these agents.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Economic and Organizational Advantages of Bictegravir/Alafenamide Tenofovir/Emtricitabine for HIV Treatment () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1144;    
    It is a cost-saving option with savings of up to 75.1% compared to some of its competitors, making it a valuable option for the National Health System in Mexico for treating HIV-1 infection in adult patients. BIC/FTC/TAF represents an interesting possibility for the rapid initiation of ART, as well as for switches, being able to optimize the clinical pathway of a patient with HIV, from an economic and organizational perspective.
  • ||||||||||  Journal:  Representation of Native Hawaiian and Pacific Islander Individuals in Clinical Trials. (Pubmed Central) -  Oct 29, 2024   
    This is especially concerning because Native Hawaiian and Pacific Islander individuals have a higher risk than other racial groups for type 2 diabetes, cancer, and several other conditions the products examined in this study treat. Given the importance of enrolling Native Hawaiian and Pacific Islander participants in clinical trials, sites should be established in key geographic regions, such as Hawai'i, and postmarket studies should be conducted within Native Hawaiian and Pacific Islander populations.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed:  Sungura: B/F/TAF to DTG/3TC Switch Study (clinicaltrials.gov) -  Oct 28, 2024   
    P3,  N=240, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment?na () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_532;    
    P3
    Larger studies are needed to confirm the clinical impact of our findings. Introduction: The ALLIANCE study showed that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir + emtricitabine/tenofovir disoproxil fumarate at achieving HIV-1 RNA suppression, and superior at achieving HBV DNA suppression at week 48 in treatment-na